Elisabeth I. Heath

May 29, 2024 | europeanurology.com | Catherine Tangen |Elisabeth I. Heath |Mark Stein

Abstract EVEREST is a phase 3 trial in patients with renal cell cancer (RCC) at intermediate-high or very high risk of recurrence after nephrectomy who were randomized to receive adjuvant everolimus or placebo. Longer recurrence-free survival (RFS) was observed with everolimus (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.72–1.00; p = 0.051), but the nominal significance level (p = 0.044) was not reached.

Feb 27, 2024 | nature.com | Nicholas A. Zorko |Yousef Zakharia |Vivek Narayan |Elisabeth I. Heath |Allison Makovec

AbstractNatural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to evaluate NK cell infiltration into tumors to develop an improved understanding of which histologies may be most amenable to NK cell-based therapies currently in the developmental pipeline.

Jul 28, 2023 | thelancet.com | Christopher Ryan |Catherine Tangen |SWOG Statistics |Elisabeth I. Heath

Background Patients undergoing resection of renal cell carcinoma are at risk of disease relapse. We evaluated the effectiveness of the mammalian target of rapamycin inhibitor everolimus administered after surgery.

May 24, 2023 | onclive.com | Alan Bryce |Elisabeth I. Heath |Benjamin H. Lowentritt |Chesapeake Urology |Edwin M. Posadas |Tian Zhang

OncologyLiveOncology FellowsSupplements And Featured PublicationsAll Publications

May 17, 2023 | onclive.com | Alan Bryce |Elisabeth I. Heath |Benjamin H. Lowentritt |Chesapeake Urology |Edwin M. Posadas |Tian Zhang

OncologyLiveOncology FellowsSupplements And Featured PublicationsAll Publications